{
    "root": "e0c726f6-8257-4dba-b2f9-d78d28097bd9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Famotidine"
    },
    "value": "20250304",
    "ingredients": [
        {
            "name": "FAMOTIDINE",
            "code": "5QZO15J2Z8"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "famotidine tablets indicated adult pediatric patients 40 kg greater treatment : active duodenal ulcer ( du ) . active gastric ulcer ( gu ) . symptomatic nonerosive gastroesophageal reflux disease ( gerd ) . erosive esophagitis due gerd , diagnosed biopsy . famotidine tablets indicated adults : treatment pathological hypersecretory conditions ( e.g . , zollinger-ellison syndrome , multiple endocrine neoplasias ) . reduction risk duodenal ulcer recurrence .",
    "contraindications": "indication recommended ( 2.1 ) adult pediatric patients 40 kg greater active du 40 mg daily ; 20 mg twice daily active gastric ulcer 40 mg daily gerd 20 mg twice daily erosive esophagitis 20 mg twice daily ; 40 mg twice daily adults pathological hypersecretory conditions 20 mg every 6 hours ; adjust patient needs ; maximum 160 mg every 6 hours risk reduction du recurrence 20 mg daily full prescribing information complete dosing information , including dosing renal impairment , recommended treatment duration . ( 2.1 , 2.2 ) ( 2.3 ) : take daily bedtime twice daily morning bedtime without food .",
    "warningsAndPrecautions": "famotidine tablets usp , 20 mg yellow , rounded square shaped , biconvex , film-coated tablets debossed \u2018 cc \u2019 one side \u2018 60 \u2019 side . bottles 30 ndc 65862-859-30bottles 100 ndc 65862-859-01bottles 500 ndc 65862-859-05bottles 1,000 ndc 65862-859-9910 x 10 unit-dose tablets ndc 65862-859-78 famotidine tablets usp , 40 mg white , rounded square shaped , biconvex , film-coated tablets debossed \u2018 cc \u2019 one side \u2018 61 \u2019 side . bottles 30 ndc 65862-860-30bottles 100 ndc 65862-860-01bottles 500 ndc 65862-860-05bottles 1,000 ndc 65862-860-9910 x 10 unit-dose tablets ndc 65862-860-78 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense usp tight , light-resistant container .",
    "adverseReactions": "famotidine tablets contraindicated patients history serious hypersensitivity ( e.g . , anaphylaxis ) famotidine histamine-2 ( h2 ) receptor antagonists .",
    "indications_original": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and\u00a0greater for the treatment of: \n                  \n                     active duodenal ulcer (DU). \n                     active gastric ulcer (GU). \n                     symptomatic nonerosive gastroesophageal reflux disease (GERD). \n                     erosive esophagitis due to GERD, diagnosed by biopsy. \n                  \n                  \n                  Famotidine tablets are indicated in adults for the: \n                  \n                     treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). \n                     reduction of the risk of duodenal ulcer recurrence.",
    "contraindications_original": "Indication Recommended Dosage (2.1) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. ( 2.1 , 2.2 ) Administration (2.3) : Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.",
    "warningsAndPrecautions_original": "Famotidine Tablets USP, 20 mg are yellow, rounded square shaped, biconvex, film-coated tablets debossed with \u2018CC\u2019 on one side and \u201860\u2019 on the other side.\n                  \n                  \n                  Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-859-30Bottles of 100\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-859-01Bottles of 500\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-859-05Bottles of 1,000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-859-9910 x 10 Unit-dose Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-859-78\n                  \n                  \n                     Famotidine Tablets USP, 40 mg are white, rounded square shaped, biconvex, film-coated tablets debossed with \u2018CC\u2019 on one side and \u201861\u2019 on the other side.\n                  \n                  Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-860-30Bottles of 100\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-860-01Bottles of 500\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-860-05Bottles of 1,000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-860-9910 x 10 Unit-dose Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65862-860-78\n                  \n                  \n                     Storage\n                  \n                  \n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in a USP tight, light-resistant container.",
    "adverseReactions_original": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other\u00a0histamine-2 (H2) receptor antagonists."
}